JP2021102605A - マイコバクテリア感染症を治療するための、アモキシシリン誘導体とアビバクタム誘導体の組み合わせ経口投与 - Google Patents

マイコバクテリア感染症を治療するための、アモキシシリン誘導体とアビバクタム誘導体の組み合わせ経口投与 Download PDF

Info

Publication number
JP2021102605A
JP2021102605A JP2020208924A JP2020208924A JP2021102605A JP 2021102605 A JP2021102605 A JP 2021102605A JP 2020208924 A JP2020208924 A JP 2020208924A JP 2020208924 A JP2020208924 A JP 2020208924A JP 2021102605 A JP2021102605 A JP 2021102605A
Authority
JP
Japan
Prior art keywords
substituted
oxy
alkyl
pharmaceutically acceptable
heterocycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020208924A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021102605A5 (https=
Inventor
ジョアキム・トリアス
Trias Joaquim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arixa Pharmaceuticals Inc
Original Assignee
Arixa Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arixa Pharmaceuticals Inc filed Critical Arixa Pharmaceuticals Inc
Publication of JP2021102605A publication Critical patent/JP2021102605A/ja
Publication of JP2021102605A5 publication Critical patent/JP2021102605A5/ja
Priority to JP2025130486A priority Critical patent/JP2025163188A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020208924A 2019-12-20 2020-12-17 マイコバクテリア感染症を治療するための、アモキシシリン誘導体とアビバクタム誘導体の組み合わせ経口投与 Pending JP2021102605A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025130486A JP2025163188A (ja) 2019-12-20 2025-08-05 マイコバクテリア感染症を治療するための、アモキシシリン誘導体とアビバクタム誘導体の組み合わせ経口投与

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962951187P 2019-12-20 2019-12-20
US62/951,187 2019-12-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025130486A Division JP2025163188A (ja) 2019-12-20 2025-08-05 マイコバクテリア感染症を治療するための、アモキシシリン誘導体とアビバクタム誘導体の組み合わせ経口投与

Publications (2)

Publication Number Publication Date
JP2021102605A true JP2021102605A (ja) 2021-07-15
JP2021102605A5 JP2021102605A5 (https=) 2023-12-20

Family

ID=73856245

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020208924A Pending JP2021102605A (ja) 2019-12-20 2020-12-17 マイコバクテリア感染症を治療するための、アモキシシリン誘導体とアビバクタム誘導体の組み合わせ経口投与
JP2025130486A Pending JP2025163188A (ja) 2019-12-20 2025-08-05 マイコバクテリア感染症を治療するための、アモキシシリン誘導体とアビバクタム誘導体の組み合わせ経口投与

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025130486A Pending JP2025163188A (ja) 2019-12-20 2025-08-05 マイコバクテリア感染症を治療するための、アモキシシリン誘導体とアビバクタム誘導体の組み合わせ経口投与

Country Status (8)

Country Link
US (2) US20210186983A1 (https=)
EP (1) EP4076451A1 (https=)
JP (2) JP2021102605A (https=)
KR (1) KR20220114629A (https=)
CN (1) CN115003302A (https=)
AU (1) AU2020405540A1 (https=)
CA (1) CA3164938A1 (https=)
WO (1) WO2021124191A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119841826B (zh) * 2024-09-30 2026-04-10 科睿迪(南京)医药科技有限公司 二氮杂二环类β-内酰胺酶抑制剂及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018208557A1 (en) * 2017-05-10 2018-11-15 Arixa Pharmaceuticals, Inc. 3-(((((2s,5r)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl)oxy)sulfonyl)oxy)-2,2-dimethylprop noate derivatives and related compounds as perorally administered profrugs of beta-lactamase inhibitors for treating bacterial infections

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022524118A (ja) * 2019-03-12 2022-04-27 アリクサ ファーマシューティカルズ、インコーポレイテッド アビバクタム誘導体の結晶形

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018208557A1 (en) * 2017-05-10 2018-11-15 Arixa Pharmaceuticals, Inc. 3-(((((2s,5r)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl)oxy)sulfonyl)oxy)-2,2-dimethylprop noate derivatives and related compounds as perorally administered profrugs of beta-lactamase inhibitors for treating bacterial infections

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J ANTIMICROB CHEMOTHER, vol. 70, JPN6024042623, 2015, pages 1051 - 1058, ISSN: 0005575963 *
J. MED. CHEM., vol. 61, JPN6024042622, 2018, pages 10340 - 10344, ISSN: 0005575962 *

Also Published As

Publication number Publication date
US20240245705A1 (en) 2024-07-25
EP4076451A1 (en) 2022-10-26
WO2021124191A1 (en) 2021-06-24
US20210186983A1 (en) 2021-06-24
AU2020405540A1 (en) 2022-06-09
CN115003302A (zh) 2022-09-02
KR20220114629A (ko) 2022-08-17
CA3164938A1 (en) 2021-06-24
JP2025163188A (ja) 2025-10-28

Similar Documents

Publication Publication Date Title
AU2024201877B2 (en) Orally administered combinations of beta-lactam antibiotics and avibactam derivatives for treating bacterial infections
JP2021165298A (ja) ベータ−ラクタマーゼ阻害剤およびその使用
AU2005215320A1 (en) Amino alcohol compound
JP2025163188A (ja) マイコバクテリア感染症を治療するための、アモキシシリン誘導体とアビバクタム誘導体の組み合わせ経口投与
AU2020237440B2 (en) Crystalline form of an avibactam derivative
JP7437847B2 (ja) レレバクタムの誘導体およびその使用
HK40083209A (en) Orally administered combinations of amoxicillin and avibactam derivatives for treating mycobacterial infections
US20070129344A1 (en) Bicyclic 6-alkylidene-penem beta-lactamase inhibitors and beta-lactam antibiotic combination: a broad spectrum antibiotic
RU2825281C1 (ru) Вводимые перорально комбинации бета-лактамных антибиотиков и производных авибактама для лечения бактериальных инфекций
CN104981238A (zh) 抗细菌化合物
HK40063686A (en) Crystalline form of an avibactam derivative
HK40072825A (en) Orally administered combinations of beta lactam antibiotics and avibactam derivatives for treating bacterial infections
NZ758795B2 (en) Atropine pharmaceutical compositions

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20220527

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20220530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231211

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231211

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241015

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241023

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250421